FindTrial
Sign In

Study to compare the impact of poor injection site rotation vs. needle reuses in causing lipohypertrophy in T2DM patients.

"LIP (Lipohypertrophy and Insulin Injection Practices) Study" - LIP

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/10/046817
Enrollment
400
Registered
2022-10-26
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

Dr Manash P Baruah Director and Consultant Endocrinologist
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of Type 2 DM from either sex on insulin therapy irrespective of duration of diabetes, type and dose of insulin. 2. Having full details of insulin injection technique, insulin type, dose, needle usage/reusage, behaviour. 3. Having HCP remarks on presence/absence lipodystrophy in the database.

Exclusion criteria

Exclusion criteria: 1. Children below 15 years 2. Elderly above 85 years. 3. Pregnant lady on insulin 4. Patients with alteration of skin texture in the insulin injection areas due to other causes such as burn/scald or trauma.

Design outcomes

Primary

MeasureTime frame
Comparision of the impact of poor injection site rotation vs. needle reuses in causing lipohypertrophy in a cohort of T2DM diabetic patients on insulin.Timepoint: 12 weeks—

Secondary

MeasureTime frame
Determination of an optimal upper cut off for the number of injection pricks which may not be significantly associated with lipohypertrophy.Timepoint: 20 weeks—

Countries

India

Contacts

Public ContactDr Manash P Baruah

Apollo Excelcare Hospital

manashb2@gmail.com9435118344

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026